Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis
Completed · Phase 2 · NCT05130970
Conditions: Idiopathic Pulmonary Fibrosis
At a glance
- Research payments reported, 2025
- $1,250
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 81
About the trial
- Sponsor
- CSL Behring
- Tested
- Garadacimab (drug), Placebo (drug)
- Dates
- Started 2022-02-03; completion 2024-01-02
- Results posted
- Yes
This is a prospective, phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of garadacimab in subjects with idiopathic pulmonary fibrosis (IPF).
From ClinicalTrials.gov, last updated 2024-12-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Csl Behring reported $1,250 in research payments for this study in 2025 (1 payments).
Products named: Andembry
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Clinical Trials Center of Middle Tennessee, LLC $1,250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.